Pharmacotherapy for treatment-refractory schizophrenia
SP Van Sant, PF Buckley - Expert opinion on pharmacotherapy, 2011 - Taylor & Francis
Introduction: Despite advances in pharmacotherapy of schizophrenia-spectrum disorders, a
large percentage of persons with schizophrenia remain at least partially nonresponsive to …
large percentage of persons with schizophrenia remain at least partially nonresponsive to …
Current treatment options and emerging agents for schizophrenia
CU Correll - The Journal of Clinical Psychiatry, 2020 - legacy.psychiatrist.com
The currently available antipsychotics mostly treat the positive symptoms of schizophrenia
and have at least one adverse effect as a potential liability. Encouraging data suggest …
and have at least one adverse effect as a potential liability. Encouraging data suggest …
Conventional antipsychotic medications for schizophrenia
LB Dixon, AF Lehman, J Levine - Schizophrenia bulletin, 1995 - academic.oup.com
This article reviews the existing evidence for the efficacy and effectiveness of conventional
antipsychotic medications in the treatment of schizophrenia. Among the issues reviewed are …
antipsychotic medications in the treatment of schizophrenia. Among the issues reviewed are …
Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology
TRE Barnes… - Journal of …, 2011 - journals.sagepub.com
These guidelines from the British Association for Psychopharmacology address the scope
and targets of pharmacological treatment for schizophrenia. A consensus meeting, involving …
and targets of pharmacological treatment for schizophrenia. A consensus meeting, involving …
[HTML][HTML] Pharmacological treatment of early-onset schizophrenia: a critical review, evidence-based clinical guidance and unmet needs
JD Lopez-Morinigo, S Leucht, C Arango - Pharmacopsychiatry, 2022 - thieme-connect.com
Early-onset schizophrenia (EOS)–onset before age 18–is linked with great disease burden
and disability. Decision-making for EOS pharmacological treatment may be challenging due …
and disability. Decision-making for EOS pharmacological treatment may be challenging due …
The pharmacological treatment of schizophrenia: How far have we come?
JM Rubio, JM Kane - Psychiatry and Clinical Neurosciences …, 2022 - Wiley Online Library
Schizophrenia is a chronic and often severe mental disorder for which antipsychotic drugs
are the cornerstone of treatment. Although the essential mechanism of action of these drugs …
are the cornerstone of treatment. Although the essential mechanism of action of these drugs …
Treatment of schizophrenia patients: comparing new-generation antipsychotics to each other
WW Fleischhacker… - Current Opinion in …, 2006 - journals.lww.com
This review covers studies wherein therapeutic effects and adverse events of these drugs in
schizophrenia patients were compared in head-to-head studies and that were published in …
schizophrenia patients were compared in head-to-head studies and that were published in …
Pharmacotherapy of schizophrenia: the past, present and future
S Akhondzadeh - Current Drug Therapy, 2006 - ingentaconnect.com
Traditionally, schizophrenia was considered to be a severe psychiatric disorder, with a
chronic course and an unfavorable outcome. Throughout history, there has been incidence …
chronic course and an unfavorable outcome. Throughout history, there has been incidence …
Emerging drugs for schizophrenia
O Agid, S Kapur, G Remington - Expert opinion on emerging drugs, 2008 - Taylor & Francis
Background/objective: Schizophrenia is a chronic and disabling psychiatric disorder that
requires lifelong medication. The past 15 years led to the introduction of a number of new …
requires lifelong medication. The past 15 years led to the introduction of a number of new …
Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities
A Krogmann, L Peters, L Von Hardenberg… - CNS …, 2019 - cambridge.org
Schizophrenia remains one of the most severe medical diseases. Current dopamine
modulating first-generation and second-generation antipsychotics target mainly positive …
modulating first-generation and second-generation antipsychotics target mainly positive …